<DOC>
	<DOCNO>NCT01287962</DOCNO>
	<brief_summary>Apatinib new kind Vascular endothelial growth factor receptor ( VEGFR ) tyrosine kinase inhibitor ( TKIs ) . The investigator finish preclinical phase I phase II clinical study apatinib find satisfactory anti-tumor activity tolerate toxicity . A disease-control rate 75 % find lung cancer patient . In present phase III trial , investigator evaluate efficacy toxicity apatinib treatment advanced non-squamous non-small cell lung cancer .</brief_summary>
	<brief_title>Apatinib Treatment Advanced Non-squamous Non-small Cell Lung Cancer</brief_title>
	<detailed_description />
	<mesh_term>Lung Neoplasms</mesh_term>
	<mesh_term>Carcinoma , Non-Small-Cell Lung</mesh_term>
	<criteria>1 . Patients 18 70 year age 2 . Documented pathological evidence advance nonsquamous nonsmall cell lung cancer measurable lesion 3 . Failure epidermalgrowthfactor receptor ( EGFR ) TKIs target treatment secondline regimens chemotherapy 4 . Eastern Cooperative Oncology Group ( ECOG ) performance status 0 1 5 . Patients recover toxic effect therapy 6 . Patients brain/meninges metastasis keep stable disease 2 month randomisation 7 . Adequate hematologic biochemical value require 1 . Presence smallcell lung cancer alone NSCLC 2 . Pregnant breastfeed woman 3 . Severe uncontrolled systemic disease clinically significant hypertension ( systolic pressure &gt; 140 mmHg，diastolic pressure &gt; 90 mmHg ) , cardiac ischemia infarction , ventricular arrhythmia ( QT ≥ 440ms ) grade 1 cardiac insufficiency 4 . Difficulties take pill ( inability swallow tablet , GI tract resection , chronic bacillary diarrhea intestinal obstruction ) 5 . Coagulation disfunction , hemorrhagic tendency receive anticoagulant therapy 6 . ≥ CTCAE 2 pneumorrhagia ≥ CTCAE 3 hemorrhage organ within 4 week 7 . Bone fracture wound cure long time 8 . Arterial thrombus phlebothrombosis within 6 month take anticoagulant agent 9 . Mental disease psychotropic substance abuse 10 . Previous treatment experimental agent within 4 week 11 . Previous treatment VEGFR、platelet derive growth factor receptor ( PDGFR ) TKIS 12 . Other coexist malignant disease ( apart basalcell carcinoma carcinoma situ uterine cervix )</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>January 2012</verification_date>
	<keyword>Apatinib</keyword>
	<keyword>Non-small Cell Lung Cancer</keyword>
	<keyword>VEGFR TKIs</keyword>
</DOC>